Catalyst Pharmaceuticals Files 8-K

Ticker: CPRX · Form: 8-K · Filed: 2025-04-09T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, disclosure

TL;DR

Catalyst Pharma filed an 8-K on 4/9 for an event on 4/8. Details pending.

AI Summary

Catalyst Pharmaceuticals, Inc. filed an 8-K on April 9, 2025, reporting an event that occurred on April 8, 2025. The filing is categorized under 'Other Events' and 'Financial Statements and Exhibits'. Specific details regarding the nature of the event or any financial implications were not provided in the excerpt.

Why It Matters

This filing indicates a material event has occurred for Catalyst Pharmaceuticals, requiring public disclosure. Investors should look for further details to understand the event's impact.

Risk Assessment

Risk Level: low — The filing itself is a routine disclosure and does not inherently present a risk, but the underlying event it reports could have varying risk implications.

Key Players & Entities

FAQ

What specific event is Catalyst Pharmaceuticals, Inc. reporting in this 8-K filing?

The provided excerpt does not specify the nature of the event reported on April 8, 2025, only that it is categorized under 'Other Events' and 'Financial Statements and Exhibits'.

When was this 8-K form filed with the SEC?

The 8-K form was filed on April 9, 2025.

What is the principal executive office address for Catalyst Pharmaceuticals, Inc.?

The principal executive office is located at 355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134.

What is Catalyst Pharmaceuticals, Inc.'s Central Index Key (CIK)?

Catalyst Pharmaceuticals, Inc.'s Central Index Key is 0001369568.

What is the SEC file number for Catalyst Pharmaceuticals, Inc.?

The SEC file number for Catalyst Pharmaceuticals, Inc. is 001-33057.

From the Filing

0001193125-25-076358.txt : 20250409 0001193125-25-076358.hdr.sgml : 20250409 20250409085512 ACCESSION NUMBER: 0001193125-25-076358 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250408 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250409 DATE AS OF CHANGE: 20250409 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 25823934 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K 1 d941124d8k.htm 8-K 8-K NASDAQ false 0001369568 0001369568 2025-04-08 2025-04-08     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 8, 2025     CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter)       Delaware   001-33057   76-0837053 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   355 Alhambra Circle   Suite 801   Coral Gables , Florida   33134 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (305) 420-3200 Not Applicable Former Name or Former address, if changed since last report     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Name of Exchange on Which Registered   Ticker Symbol Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01 Other Events On April 8, 2025, the Company issued a press release reporting that its sub-licensee in Canada, Kye Pharmaceuticals, Inc., has announced that Health Canada has accepted the New Drug Submission for AGAMREE ® , a novel corticosteroid treatment for Duchenne Muscular Dystrophy (DMD), for review. The submission has been granted Priority Review, expediting the regulatory process w

View on Read The Filing